A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer
A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Haijun Li, MS
- Phone Number: 1625 86-025-85560000
- Email: lihaijun@simcere.com
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Bethune Hospital of Jilin University
-
Contact:
- Yanhua Ding
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Hospital of Zhejiang Province
-
Contact:
- Nong Xu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological/cytological confirmed unresectable metastatic colorectal cancer patients who have failed first-line oxaliplatin-based chemotherapy
- At least one measurable lesion (according to RECIST 1.1 )
- At least 4 weeks from the last chemotherapy. If patients received anti-tumor biological products, at least four t1/2 of washout period is needed
- Toxicity from previous treatment has to restore to ≤ grade 1 (NCI CTC4.0)
- ECOG performance status 0-1
- Life expectancy ≥ 3 months
- Adequate hematologic function: ANC ≥ 1.5 × 10^9 /L, HB ≥ 90 g /L (blood transfusion allowed), PLT ≥ 100 ×10^9 /L; Adequate hepatic function: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN (patients with liver metastases ALT ≤ 5 × ULN, AST ≤ 5 × ULN); Adequate renal function: creatinine ≤ 1 × ULN; Coagulation function: INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN
- Patients of childbearing potential (male and female) must agree to use reliable methods of contraception until at least 12 weeks after the last dose
- Patients signed written inform consent
- Willingness and capability to communicate with investigators and to comply with protocol requirements
Exclusion Criteria:
- HCV, TP or HIV antibody positive
- Previously received anti-VEGF protein drugs, such as Bevacizumab,Sevacizumab
- Previously treated with irinotecan
- History of dihydropyrimidine dehydrogenase deficiency
- Patients with alcohol or drug dependence
- Participation in other clinical trials within 4 weeks before enrollment
- Active or chronic hepatitis B infection with HBV DNA > 1.0 * 10^3 IU/mL
- Serious infection requiring intravenous antibiotic therapy
- Symptomatic brain metastases
- Patients with proteinuria at screening (urine protein ≥ 1+)
- History of abdominal fistula, gastrointestinal perforation, abdominal abscess within 6 months prior to enrollment
- History of intestinal obstruction, inflammatory bowel disease, or other intestinal diseases with chronic diarrhea as the major symptom
- Serious non-healing wounds, ulcers or fractures
- Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to enrollment
- Active bleeding within 3 months prior to enrollment
- Bleeding diathesis or coagulation disorder
- History of arterial or venous thrombosis
- History of myocardial infarction or stroke within 6 months prior to enrollment
- Unstable angina, congestive heart failure, New York Heart Association (NYHA) class II heart failure, uncontrollable arrhythmia, uncontrolled hypertension
- Expected to receive surgery during the study or within 1 month after the last dose
- The investigators consider the patients are not suitable for this trial
- Pregnant and lactating women
- Known allergies to any excipient in the study drug
- Patients can not complete this study for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sevacizumab+FOLFIRI
Two weeks as one cycle.
Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
|
escalating doses of Sevacizumab : 3mg/kg,4mg/kg,5mg/kg
Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Tolerated Dose (MTD)
Time Frame: up to 56 days
|
up to 56 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse Events (NCI-CTC 4.0)
Time Frame: 28 days after the last dose
|
28 days after the last dose
|
|
Plasma pharmacokinetics (PK) parameters for Sevacizumab
Time Frame: Cycle 1(Day3, Day4, Day7, Day10, Day13); Cycle 2-4(Day1);Cycle 4(Day1, Day2, Day5, Day8 ,Day11)
|
Cycle 1(Day3, Day4, Day7, Day10, Day13); Cycle 2-4(Day1);Cycle 4(Day1, Day2, Day5, Day8 ,Day11)
|
|
Plasma pharmacokinetics (PK) parameters (Cmax, Tmax, AUC, T1/2) for Irinotecan and its major metabolite SN-38
Time Frame: Day1, Day2, Day3, Day15, Day16, Day17
|
Day1, Day2, Day3, Day15, Day16, Day17
|
|
Plasma pharmacokinetics (PK) parameters for 5-FU
Time Frame: Day1, Day3, Day15, Day17
|
Day1, Day3, Day15, Day17
|
|
Potential biomarkers, including VEGF and ADA
Time Frame: VEGF:Cycle 1(Day3, Day4, Day7, Day10, Day13); Cycle 2-4(Day1);Cycle 4(Day1, Day2, Day5, Day8, Day11); ADA : within 15 minutes before each Sevacizumab administration
|
VEGF:Cycle 1(Day3, Day4, Day7, Day10, Day13); Cycle 2-4(Day1);Cycle 4(Day1, Day2, Day5, Day8, Day11); ADA : within 15 minutes before each Sevacizumab administration
|
|
Objective Response Rate (ORR)
Time Frame: up to 3 years from date of registration
|
up to 3 years from date of registration
|
|
Disease Control Rate (DCR)
Time Frame: up to 3 years from date of registration
|
up to 3 years from date of registration
|
|
Progression Free Survival (PFS)
Time Frame: up to 3 years from date of registration
|
up to 3 years from date of registration
|
|
Overall Survival (OS)
Time Frame: up to 3 years from date of registration
|
up to 3 years from date of registration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jin Li, MD, Fudan University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Leucovorin
- Irinotecan
Other Study ID Numbers
Other Study ID Numbers
- SIM129-mCRC-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.